Novavax’s Adjuvanted COVID-19 Vaccine Caused Severe Adverse Reactions in Clinical Trials - Hallo friendsTOP POLENNEWS, In the article you read this time with the title Novavax’s Adjuvanted COVID-19 Vaccine Caused Severe Adverse Reactions in Clinical Trials, We have prepared this article for you to read and retrieve information therein. Hopefully the contents of postings Article cultur, Article economic, Article health, Article news, Article politique, Article sport, We write this you can understand. Alright, good read.

Title : Novavax’s Adjuvanted COVID-19 Vaccine Caused Severe Adverse Reactions in Clinical Trials
link : Novavax’s Adjuvanted COVID-19 Vaccine Caused Severe Adverse Reactions in Clinical Trials

Novavax’s Adjuvanted COVID-19 Vaccine Caused Severe Adverse Reactions in Clinical Trials

Novavax’s Adjuvanted COVID-19 Vaccine Caused Severe Adverse Reactions in Clinical Trials

by Marco Cáceres

Published September 14, 2020 | Vaccination, Risk & Failure Reports

Biotechnology company Novavax, Inc. of Gaithersburg, Maryland recently made public the results of the Phase 1 part of a Phase 1/2 human clinical trial for its experimental NVX-CoV2373 vaccine for COVID-19. According to Novavax, “NVX‑CoV2373 was created using Novavax’s recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and contains Novavax’s patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.”¹
The clinical trial involved 131 healthy adults between 18-59 years of age. The results were published in The New England Journal of Medicine (NEJM) on Sept. 2, 2020.²

Novavax COVID-19 Vaccine Contains Strong Saponin-Based Adjuvant

Of the 131 participants in the clinical trial,, which began on May 26, 2020, 83 were given the NVX-CoV2373 vaccine containing the Matrix-M1 adjuvant to help stimulate an immune response to produce a strong antibody response. Matrix-M1 contains nm (nanometers) of nanoparticles composed of Quillaja saponins, cholesterol and phospholipid. Quillaja saponins are chemical compounds extracted from the soapbox tree. They are used by the food industry as “emulsifiers in beverages and food additives.”^{2 3 4 5 6}
In the cosmetics industry, Quillaja saponins (from the Latin “sapo,” meaning soap) are used as “antidandruff, cleansing, emulsifying, foaming, masking, moisturizing, skin conditioning, and surfactant agents.”⁶
Of the remaining trial participants, 25 were given the NVX-CoV2373 vaccine without the Matrix-M1 adjuvant and 23 participants were given a placebo of sterile 0.9 percent normal saline. Each participant received two intrasmuscular injections in the deltoid muscle. The injections were given three weeks apart.²
Trial participants were divided into five group: group A, group B, group C, group D and group E. The 23 participants in group A received two doses of the placebo; 25 participants in group B received 25-μg (microgram) doses of the NVX-CoV2373 vaccine without the Matrix-M1 adjuvant; 29 participants in group C received 5-μg doses of NVX-CoV2373 with Matrix-M1; 28 participants in group D received 25-μg doses of NVX-CoV2373 with Matrix-M1; and 26 participants in group E received a single 25-μg dose of NVX-CoV2373 with Matrix-M1 followed by a single dose of placebo.²

Severe Adverse Events Occurred in Novavax’s COVID-19 Vaccine Clinical Trials

According to the results of the clinical trial, two of the 83 participants (one each in groups D and E) suffered “severe adverse events” (headache, fatigue and malaise) after the first dose. Two participants—one each in groups A and E—had “reactogenicity events” (fatigue, malaise and tenderness). A reactogenicity event is an “expected” adverse event following vaccination.^{7 8}
Following administration of the second dose, one participant in group D had a “severe local event” (tenderness) and eight participants—one or two in each group—had “severe systemic events.” The most common of these severe systemic events were joint pain and fatigue. One participant in group D developed a fever of 100.58°F.²

---

References:

  1986: The Act, adverse events, Marco Cáceres, Matrix-M1, National Vaccine Information Center, NEJM, NVIC, NVX-CoV2373, placebo, Quillaja saponins, reactogenicity events, severe systemic events, The New England Journal of Medicine, The Vaccine Reaction

Thus Article Novavax’s Adjuvanted COVID-19 Vaccine Caused Severe Adverse Reactions in Clinical Trials

That's an article Novavax’s Adjuvanted COVID-19 Vaccine Caused Severe Adverse Reactions in Clinical Trials This time, hopefully can give benefits to all of you. well, see you in posting other articles.

You are now reading the article Novavax’s Adjuvanted COVID-19 Vaccine Caused Severe Adverse Reactions in Clinical Trials with the link address https://polennews.blogspot.com/2020/09/novavaxs-adjuvanted-covid-19-vaccine.html

Tweet

Subscribe to receive free email updates: